MedPath

Rocuronium

Generic Name
Rocuronium
Drug Type
Small Molecule
Chemical Formula
C32H53N2O4
CAS Number
143558-00-3
Unique Ingredient Identifier
WRE554RFEZ
Background

Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.

Indication

For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Associated Conditions
Muscle fasciculation caused by succinylcholine
Associated Therapies
Curarization therapy, Neuromuscular blocking therapy, Facilitation of small bowel intubation therapy

Enhanced Recovery Protocol Reduces Hospital Stay for Elderly Patients Undergoing Pelvic Floor Surgery

A new clinical trial demonstrates that Enhanced Recovery After Surgery (ERAS) protocol significantly improves outcomes for older patients undergoing transvaginal pelvic floor reconstruction. The study found reduced post-operative hospital stays, decreased opioid use, and lower complication rates compared to conventional care, marking an important advancement in geriatric surgical care.

Lung Protective Ventilation Guided by Driving Pressure Improves Pulmonary Outcomes in Heart Transplant Patients

A study on patients undergoing orthotopic heart transplantation found that lung protective ventilation guided by driving pressure significantly improves pulmonary outcomes compared to conventional methods. The research highlights the importance of tailored ventilation strategies in reducing postoperative pulmonary complications.

Dexmedetomidine Nasal Spray Shows Promise in Reducing Emergence Agitation After ENT Surgery

• A randomized, double-blind, placebo-controlled trial is underway to evaluate dexmedetomidine nasal spray's effectiveness in reducing emergence agitation (EA) in adults after ENT surgery. • The study will assess the incidence and severity of EA, alongside postoperative pain, sleep quality, anxiety, and delirium, comparing dexmedetomidine with a saline placebo. • Researchers aim to determine if preoperative dexmedetomidine nasal spray can decrease EA rates and improve postoperative recovery following ENT procedures. • The trial includes 160 adult patients and will monitor various perioperative data points to provide a comprehensive analysis of dexmedetomidine's effects.

Low Blood S-methyl-5-thioadenosine Linked to Postoperative Cognitive Decline

• A recent study reveals that low levels of S-methyl-5-thioadenosine (MTA) in the blood are associated with delayed neurocognitive recovery (dNCR) following surgery in elderly patients. • The research indicates that anesthesia and surgery can lead to a decrease in MTA levels, potentially contributing to postoperative cognitive dysfunction. • Supplementation with MTA or its precursor methionine in animal models showed promise in mitigating cognitive impairment after surgical procedures. • These findings suggest that monitoring and potentially modulating MTA levels could be a therapeutic strategy to reduce postoperative cognitive issues.

Erector Spinae Plane Block vs. Serratus Anterior Plane Block for Post-LSG Analgesia: A Randomized Trial

• A randomized clinical trial is underway to compare the efficacy of Erector Spinae Plane Block (ESB) versus Serratus Anterior Plane Block (SAPB) for pain management after Laparoscopic Sleeve Gastrectomy (LSG). • The study aims to assess the quality of recovery at 24 hours postoperatively using the QoR-15 score as the primary outcome measure. • Secondary outcomes include pain scores, opioid consumption, time to first analgesia, and incidence of postoperative nausea and vomiting. • The trial employs an opioid-sparing analgesic approach and involves 70 patients undergoing elective LSG surgery at Galway University Hospital.
© Copyright 2025. All Rights Reserved by MedPath